A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
Background: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/21/5566 |
| _version_ | 1797512732771090432 |
|---|---|
| author | Francisco Aya Mariana Benegas Nuria Viñolas Roxana Reyes Ivan Vollmer Ainara Arcocha Marcelo Sánchez Noemi Reguart |
| author_facet | Francisco Aya Mariana Benegas Nuria Viñolas Roxana Reyes Ivan Vollmer Ainara Arcocha Marcelo Sánchez Noemi Reguart |
| author_sort | Francisco Aya |
| collection | DOAJ |
| description | Background: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab. Results: All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant (<i>p</i> = 0.013), whereas all perfusion parameters showed significant differences between baseline and day +42 (<i>p</i> = 0.003, <i>p</i> = 0.049, and <i>p</i> = 0.002, respectively). Among the 16 patients evaluable for efficacy, a significant decline in BV at day +7 from baseline was observed in tumors with no response (<i>p</i> = 0.0418). Conclusions: Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs. |
| first_indexed | 2024-03-10T06:04:56Z |
| format | Article |
| id | doaj.art-bdd94ad08139484392fa6d44064a9979 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:04:56Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-bdd94ad08139484392fa6d44064a99792023-11-22T20:37:09ZengMDPI AGCancers2072-66942021-11-011321556610.3390/cancers13215566A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLCFrancisco Aya0Mariana Benegas1Nuria Viñolas2Roxana Reyes3Ivan Vollmer4Ainara Arcocha5Marcelo Sánchez6Noemi Reguart7Department of Medical Oncology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Radiology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Medical Oncology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Medical Oncology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Radiology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Medical Oncology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Radiology, Hospital Clínic, 08036 Barcelona, SpainDepartment of Medical Oncology, Hospital Clínic, 08036 Barcelona, SpainBackground: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab. Results: All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant (<i>p</i> = 0.013), whereas all perfusion parameters showed significant differences between baseline and day +42 (<i>p</i> = 0.003, <i>p</i> = 0.049, and <i>p</i> = 0.002, respectively). Among the 16 patients evaluable for efficacy, a significant decline in BV at day +7 from baseline was observed in tumors with no response (<i>p</i> = 0.0418). Conclusions: Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs.https://www.mdpi.com/2072-6694/13/21/5566imagingperfusion CTNSCLCantiangiogenicbiomarkerstumor perfusion |
| spellingShingle | Francisco Aya Mariana Benegas Nuria Viñolas Roxana Reyes Ivan Vollmer Ainara Arcocha Marcelo Sánchez Noemi Reguart A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC Cancers imaging perfusion CT NSCLC antiangiogenic biomarkers tumor perfusion |
| title | A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC |
| title_full | A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC |
| title_fullStr | A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC |
| title_full_unstemmed | A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC |
| title_short | A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC |
| title_sort | pilot study to evaluate early predictive value of thorax perfusion ct in advanced nsclc |
| topic | imaging perfusion CT NSCLC antiangiogenic biomarkers tumor perfusion |
| url | https://www.mdpi.com/2072-6694/13/21/5566 |
| work_keys_str_mv | AT franciscoaya apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT marianabenegas apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT nuriavinolas apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT roxanareyes apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT ivanvollmer apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT ainaraarcocha apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT marcelosanchez apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT noemireguart apilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT franciscoaya pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT marianabenegas pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT nuriavinolas pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT roxanareyes pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT ivanvollmer pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT ainaraarcocha pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT marcelosanchez pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc AT noemireguart pilotstudytoevaluateearlypredictivevalueofthoraxperfusionctinadvancednsclc |